Danske Capital: Exit is a massive boost for Genmab
Celgene’s decision to walk away from a licensing deal for a rival drug to Genmab’s daratumumab is an underestimated reinforcement of the Danish company’s position on the market, says Danske Capital, adding that Celgene's next move could involve fellow pharma company Sanofi.
BY BENJAMIN WERNER CHRISTENSEN & MARTIN HAVTORN PETERSEN
One of the major developments on the global biotech stage last month was AbbVie’s 21 billion dollars acquisition of Pharmacyclics and the company’s drug Imbruvica, says Danske Capital’s Claus Henrik Johansen. But another event could have a bigger impact on things in this part of the world, not least for the biotech company Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
This is Genmab’s main focus for 2015
For abonnenter
Danske: Genmab partner might accelerate launch
For abonnenter
Increased belief in Genmab’s potential blockbuster
For abonnenter
